Roche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis
May 17, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS)...
Global Multiple Sclerosis Treatment Market Report 2023: Sector is Projected to Reach $38.41 Million in 2031 at a CAGR of 4.3%
May 03, 2023 10:53 ET
|
Research and Markets
Dublin, May 03, 2023 (GLOBE NEWSWIRE) -- The "Global Multiple Sclerosis Treatment Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global...
[Ad-hoc-Mitteilung gemäss Art. 53 LR] Roche erzielt im ersten Quartal ein starkes Verkaufswachstum im Basisgeschäft beider Divisionen; Rückgang der Konzernverkäufe aufgrund der erwartungsgemäss geringeren Nachfrage nach COVID-19-Tests
April 26, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 26. April 2023 Wie erwartet führt die stark rückläufige Nachfrage nach COVID-19-Tests zu einer Abnahme der Konzernverkäufe (-3%1 zu konstanten Wechselkursen [CER] und -7% in Schweizer...
[Annonce événementielle selon l’art. 53 RC] Roche annonce une forte croissance des ventes dans les activités de base de ses deux divisions au T1 ; le recul des ventes du Groupe est dû à la baisse attendue de la demande de tests COVID-19
April 26, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Bâle, le 26 avril 2023 Comme attendu, la baisse significative de la demande de tests COVID-19 entraîne une diminution des ventes du Groupe (-3 %1 à taux de change constants [TCC] et -7 % en francs...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
April 26, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 26 April 2023 As expected, significantly lower demand for COVID-19 tests leads to a decrease in Group sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this...
Foundery Innovations Establishes Scientific Advisory Board with Appointment of Key Opinion Leaders in Immunology and Oncology
March 28, 2023 08:00 ET
|
Foundery Innovations
SAN FRANCISCO, March 28, 2023 (GLOBE NEWSWIRE) -- Foundery Innovations (“Foundery”), a biotechnology venture studio focused on translating immunology discoveries into drug candidates, announced the...
argenx Announces Planned Transition of Chief Operating Officer
March 02, 2023 01:00 ET
|
argenx SE
Karen Massey appointed as Chief Operating Officer, effective March 13, 2023Keith Woods to retire and serve as Advisor on argenx Board of Directors March 2, 2023 Amsterdam, the Netherlands — argenx...
Multiple Sclerosis Drugs Global Market Report 2023
February 08, 2023 13:18 ET
|
ReportLinker
New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Multiple Sclerosis Drugs Global Market Report 2023" -...
[Annonce événementielle au sens de l’art. 53 RC] Roche affiche de bons résultats pour 2022 en dépit d'une baisse de la demande de produits liés au COVID-19
February 02, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Bâle, le 2 février 2023 Le chiffre d’affaires consolidé augmente de 2%1 à taux de change constants (TCC) et de 1% en francs suisses, malgré la...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
February 02, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 2 February 2023 Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division sales...